Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33806241

Citations 10

Authors

Yoojin Seo

Min-Jung Kang

Hyung-Sik Kim

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cells (MSCs) have been developed as cell therapeutics for various immune disorders using their immunoregulatory properties mainly exerted by their paracrine functions. However, variation among cells from different donors, as well as rapid clearance after transplantation have impaired the uniform efficacy of MSCs and limited their application. Recently, several strategies to overcome this limitation have been suggested and proven in pre-clinical settings. Therefore, in this review article, we will update the knowledge on bioengineering strategies to improve the immunomodulatory functions of MSCs, including genetic modification and physical engineering.

Citing Articles

Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment.

Kangari P, Salahlou R, Vandghanooni S Adv Pharm Bull. 2024; 14(3):574-590.

PMID: 39494266 PMC: 11530882. DOI: 10.34172/apb.2024.052.

Autologous Fat Grafting-A Panacea for Scar Tissue Therapy?.

Ahmad N, Anker A, Klein S, Dean J, Knoedler L, Remy K Cells. 2024; 13(16).

PMID: 39195271 PMC: 11352477. DOI: 10.3390/cells13161384.

Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources.

Kazem Arki M, Moeinabadi-Bidgoli K, Niknam B, Mohammadi P, Hassan M, Hossein-Khannazer N Heliyon. 2024; 10(2):e24948.

PMID: 38312681 PMC: 10835001. DOI: 10.1016/j.heliyon.2024.e24948.

Integrin beta 3-overexpressing mesenchymal stromal cells display enhanced homing and can reduce atherosclerotic plaque.

Hu H, Xiao X, Li T, Liu D, Geng X, Han M World J Stem Cells. 2023; 15(9):931-946.

PMID: 37900938 PMC: 10600744. DOI: 10.4252/wjsc.v15.i9.931.

Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.

Tian C, Zhang Y, Yang M, Xu H, Zhu M, Yao J J Inflamm Res. 2023; 16:2089-2119.

PMID: 37215379 PMC: 10199681. DOI: 10.2147/JIR.S400447.

References

Negi N, Griffin M . Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Stem Cells. 2020; 38(5):596-605. PMC: 7217190. DOI: 10.1002/stem.3151. View

Luz-Crawford P, Kurte M, Bravo-Alegria J, Contreras R, Nova-Lamperti E, Tejedor G . Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013; 4(3):65. PMC: 3706898. DOI: 10.1186/scrt216. View

Zheng G, Qiu G, Ge M, He J, Huang L, Chen P . Human adipose-derived mesenchymal stem cells alleviate obliterative bronchiolitis in a murine model via IDO. Respir Res. 2017; 18(1):119. PMC: 5472885. DOI: 10.1186/s12931-017-0599-5. View

Garcia J, Quiros M, Han W, OLeary M, Cox G, Nusrat A . IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials. 2019; 220:119403. PMC: 6717550. DOI: 10.1016/j.biomaterials.2019.119403. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38(6):1745-55. PMC: 3021120. DOI: 10.1002/eji.200738129. View

Yang J, Seo Y, Shin T, Ahn J, Oh S, Shin Y . Extracellular Vesicles from SOD3-Transduced Stem Cells Exhibit Improved Immunomodulatory Abilities in the Murine Dermatitis Model. Antioxidants (Basel). 2020; 9(11). PMC: 7700433. DOI: 10.3390/antiox9111165. View

Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K . T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010; 162(1):1-11. PMC: 2990924. DOI: 10.1111/j.1365-2249.2010.04143.x. View

10.

Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V . 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018; 14(4):910-919. PMC: 6040128. DOI: 10.5114/aoms.2016.63743. View

11.

Moll G, Ankrum J, Kamhieh-Milz J, Bieback K, Ringden O, Volk H . Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol Med. 2019; 25(2):149-163. DOI: 10.1016/j.molmed.2018.12.006. View

12.

Zimmermann J, McDevitt T . Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. Cytotherapy. 2013; 16(3):331-45. DOI: 10.1016/j.jcyt.2013.09.004. View

13.

Sangiorgi B, Panepucci R . Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD. Stem Cells Int. 2016; 2016:9434250. PMC: 5050362. DOI: 10.1155/2016/9434250. View

14.

Uniken Venema W, Voskuil M, Dijkstra G, Weersma R, Festen E . The genetic background of inflammatory bowel disease: from correlation to causality. J Pathol. 2016; 241(2):146-158. DOI: 10.1002/path.4817. View

15.

Kabat M, Bobkov I, Kumar S, Grumet M . Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?. Stem Cells Transl Med. 2019; 9(1):17-27. PMC: 6954709. DOI: 10.1002/sctm.19-0202. View

16.

Silva D, Souza B, Vasconcelos J, Azevedo C, Valim C, Paredes B . Granulocyte-Colony Stimulating Factor-Overexpressing Mesenchymal Stem Cells Exhibit Enhanced Immunomodulatory Actions Through the Recruitment of Suppressor Cells in Experimental Chagas Disease Cardiomyopathy. Front Immunol. 2018; 9:1449. PMC: 6036245. DOI: 10.3389/fimmu.2018.01449. View

17.

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

18.

Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E . Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008; 112(13):4991-8. DOI: 10.1182/blood-2008-07-166892. View

19.

Crop M, Baan C, Korevaar S, IJzermans J, Pescatori M, Stubbs A . Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol. 2010; 162(3):474-86. PMC: 3026550. DOI: 10.1111/j.1365-2249.2010.04256.x. View

20.

Stucky E, Schloss R, Yarmush M, Shreiber D . Alginate micro-encapsulation of mesenchymal stromal cells enhances modulation of the neuro-inflammatory response. Cytotherapy. 2015; 17(10):1353-64. PMC: 5928499. DOI: 10.1016/j.jcyt.2015.05.002. View